P/E at 36.27 vs Industry's 36.64: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: A Close Match to Industry Norms

The pharmaceutical giant's P/E ratio of 36.27 sits just below the Pharmaceuticals & Biotechnology sector average of 36.64, signalling that the market values Sun Pharmaceutical Industries Ltd in line with its peers. This valuation level suggests investors are pricing in steady earnings growth consistent with sector expectations rather than a significant premium or discount. Given the company's large-cap status with a market capitalisation of ₹4,58,249 crores, this alignment with industry valuation metrics reflects a mature market perception of its earnings stability and growth prospects. However, Sun Pharma's P/E is notably lower than the sector's peak valuations seen in recent years, indicating a more cautious stance by investors amid evolving market conditions.

Performance Across Timeframes: Divergent Momentum

Examining returns over multiple periods reveals a complex performance profile. Over one year, Sun Pharmaceutical Industries Ltd has appreciated by 14.70%, comfortably outperforming the Sensex's 5.28% decline during the same period. This outperformance extends to the year-to-date figure, where the stock has gained 10.49% against the Sensex's 9.26% loss. However, the shorter-term returns tell a different story. The stock has declined by 2.10% over the past month, underperforming the Sensex's 1.66% gain, though it rebounded with a 3.20% increase over the last three months, slightly ahead of the Sensex's 1.09% rise. This oscillation suggests a period of consolidation or sector-specific headwinds impacting near-term sentiment — is this a temporary correction or a sign of shifting fundamentals?

Moving Average Configuration: Mixed Technical Signals

The technical setup for Sun Pharmaceutical Industries Ltd presents a nuanced picture. The stock price currently trades above its 5-day, 100-day, and 200-day moving averages, indicating some underlying strength and resilience in the short and long term. However, it remains below the 20-day and 50-day moving averages, which often serve as key indicators of medium-term momentum. This configuration suggests the stock is experiencing a recent bounce within a broader consolidation phase rather than a clear breakout or breakdown. The two-day consecutive gain, amounting to a 0.53% rise, supports this interpretation of tentative recovery — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Sector Context: Mixed Results Amidst Broad Stability

The Pharmaceuticals & Biotechnology sector has seen 34 companies declare results recently, with 14 reporting positive outcomes, 15 flat, and 5 negative. This distribution indicates a broadly stable sector environment with pockets of both strength and weakness. Sun Pharmaceutical Industries Ltd appears to be navigating this mixed landscape effectively, as reflected in its relative outperformance over the past year and its valuation close to the sector average. The sector's overall performance may be influencing the stock's short-term volatility, especially given the recent underperformance over the last month.

Rating Context: Previously Rated Buy, Now Reassessed

MarketsMOJO had previously rated Sun Pharmaceutical Industries Ltd as Buy, but the rating was updated on 17 Aug 2026. While the current rating is not disclosed, the reassessment reflects a recalibration of the stock's outlook based on recent performance, valuation, and technical factors. The stock's Mojo Score stands at 67.0, indicating a moderate level of confidence in its fundamentals and market position. This rating update invites investors to consider the implications of the stock's current valuation and momentum — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Conclusion: A Balanced View from Valuation, Performance, and Technicals

The data on Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock trading at a valuation closely aligned with its sector peers. Its one-year and year-to-date returns demonstrate solid outperformance relative to the Sensex, though recent monthly declines highlight some short-term challenges. The mixed moving average configuration suggests a tentative recovery phase rather than a decisive trend shift. Coupled with a sector environment showing a balance of positive and flat results, the stock's updated rating from a previous Buy invites a closer look at its current standing — what is the current rating for Sun Pharmaceutical Industries Ltd?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →